S1PR1 and glaucoma: In line with results obtained with our injury model, FTY720 has already shown a protective effect in several diseases because of its impact on immune cell migration and vascular permeability via the S1p1 signaling, e.g., in diabetic retinopathy [57], retinal dystrophy [58], light-induced degeneration [59], and glaucoma [60], choroidal neovascularization [61], uveitis [62], and retinitis pigmentosa [63].